Citius Pharmaceuticals
CTXR
39 hedge funds and large institutions have $915K invested in Citius Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 9 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
3% less funds holding
Funds holding: 40 → 39 (-1)
3.83% less ownership
Funds ownership: 8.37% → 4.55% (-3.8%)
50% less capital inflows, than outflows
Capital inflows: $391K | Capital outflows: $786K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$95.8K |
| 2 |
HRT Financial
New York
|
+$48.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19.3K |
| 4 |
Miller Financial Services
Marshall,
Michigan
|
+$11.3K |
| 5 |
Jane Street
New York
|
+$3.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Heights Capital Management
San Francisco,
California
|
-$622K |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
-$69.3K |
| 3 |
Two Sigma Investments
New York
|
-$38.5K |
| 4 |
Two Sigma Securities
New York
|
-$22.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.3K |
CTXR Hedge Fund Activity: Q1 2026 in Review
39 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2026, worth a combined $915K — down 32% from $1.35M a quarter earlier.
Fund positioning in CTXR was balanced in Q1 2026: 9 funds opened new positions, 9 closed out, 8 added to existing stakes and 6 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $95.8K. The largest seller was Heights Capital Management, exiting entirely with an estimated $622K sold.
- 39 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2026, down from 40 in Q4 2025.
- Funds reported $915K of Citius Pharmaceuticals stock for Q1 2026, down 32% quarter-over-quarter.
- 9 funds opened new Citius Pharmaceuticals positions in Q1 2026 and 9 closed out, a net change of 0 holders.
- The largest Citius Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $95.8K added.
- The largest Citius Pharmaceuticals seller in Q1 2026 was Heights Capital Management, an estimated $622K sold.
Based on aggregated 13F filings for Q1 2026.